Accuray Incorporated has debuted the Accuray Stellar* Solution, a tool set designed to empower clinical teams to address the evolving treatment needs of patients undergoing radiotherapy.

“Innovations in radiation medicine, such as adaptive radiotherapy, are enabling clinicians to deliver more precise treatments that can lead to better tumor control and potentially higher survival rates. Our goal with Accuray Stellar is to provide tools that make it simple, fast and practical for medical teams to adopt adaptive radiotherapy techniques where needed, regardless of the stage of the patient’s cancer journey. The solution reflects our commitment to innovating with purpose and compassion, and to redefining what’s possible in personalized, radiotherapy treatments,” Accuray President/CEO Suzanne Winter said.

To broaden the reach of cancer care, Accuray Stellar easily integrates with the company’s proprietary software and hardware solutions—and vendor partner technologies—expanding the range of available radiation delivery options and streamlining patient treatment workflow.

With Accuray Stellar, clinicians have access to a solution capable of numerous delivery modalities, from image-guided radiation therapy (IMRT) to stereotactic body radiation therapy (SBRT) treatments and surface-guided ration therapy (SGRT), to optimize outcomes for standard radiation therapy indications including breast, prostate, lung, and head and neck cancers, in addition to complex treatments such as total marrow irradiation.

Accuray Stellar accurately delivers radiation while correcting for changes in tumor size or shape and patient or tumor movement that can occur while patients undergo care. The solution offers a versatile and simplified path to adaptive radiotherapy developed to provide the foundation for adaptive care that can evolve with each patient’s needs, according to the company. The adaptive suite ranges from real-time motion tracking and correction, with Synchrony technology to offline adaptive protocols featuring PreciseART, as well as an online-adaptive ready interface (a prerequisite for OART**), providing the foundation for adaptive care.

Medical care teams can also leverage one of the company’s latest innovations, Adapt LTE*** powered by Accuray Cenos, only available on Accuray Stellar. Adapt LTE retrospectively evaluates previously delivered Accuray Precision treatment plans against original therapy objectives. It leverages adaptive tools to analyze historical treatment data to help clarify clinical decision pathways. It is designed for training purposes or post-treatment evaluation, enabling clinicians to build greater confidence and consistency in planning, contouring, and determining the appropriate use of adaptive technologies. This tool allows clinicians to learn, trial and evaluate.

ClearRT helical kVCT imaging provides the foundation for Accuray adaptive radiotherapy technology. ClearRT is designed to acquire high resolution images with ease and speed, providing healthcare professionals with exceptional clarity of the tumor and surrounding anatomy. Better clarity in imaging helps clinicians make more informed treatment decisions and improves patient care quality.

Accuray develops market-changing solutions to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier. The company strives to provide tools in radiation therapy for oncology, neuro-radiosurgery, and beyond, as it partners with clinicians and administrators. Accuray is headquartered in Madison, Wis., with facilities worldwide.

* The Accuray Stellar System is currently available for the U.S. market and is subject to international regulatory approval or licensing processes.
** OART is Online Adaptive Radiation Therapy
*** Adapt LTE is currently available for the U.S. market and is subject to international regulatory approval or licensing processes. LTE stands for Learn, Trial, and Evaluate.